Intra-cellular Therapies, Inc.

Mitokor, Inc.

Acadia Pharmaceuticals Inc.

Geodynamics, Inc.

Migenix, Inc.

Cp Manufacturing, Inc.

Snap-on Inc.

Cape Analytics, Inc.

Treehouse Biotech, Inc.

Other

University of California

Fmc Corporation

Molycorp, Inc.

Smith & Loveless Inc.

Robert E Davis

Peng Li

Lawrence P Wennogle

Sharon Mates

Kimberly Vanover

Mark R Brann

David M Weiner

Soumitra S Ghosh

Carl-Magnus A Andersson

Allan K Uldam

Qiang Zhang

Gretchen Snyder

Christen M Anderson

William Christensen Clevenger

Corinna Herrnstadt

Wei Yao

Sandra Eileen Wiley

Walter H Moos

Scott W Miller

Tomas R Szabo

John Thomas Hardesty

Shelby Lee Sullivan

Yazhong Pei

Johnny Joslin

David S Wesson

Hailin Zheng

Timothy G Ruther

Nicholas Davis

Terrell Saltarelli

Eoin D Fahy

Jason Ansley

Michel B Alberry

Anne N Murphy

Anthony J Cichy

Kevin R George

John Charles Tomesch

Michael D Wroblicky

Joseph Hendrick

Wayne O Rosenthal

Jeremy Castaneda

Giacomo Vianello

Jacob Black

David Kass

Graham Buckton

Alexander Y Andreyev

Toru Hashimoto

Luciano G Frigeri

Norman Nash

John K Clark

Jonathan M Fisher

Sean Colvin

Mark Hooper

Thomas Smeltzer

Abbas Haider

John S Kiely

John L Burba, Iii

Gonul Velicelebi

Ernest L Baker

Aaron Holmberg

Frank G Weis

Yuhei Yamamoto

Allen Fienberg

Takashi Abe

Arthur Daniels

Hideaki Maruyama

James Douglas Weller

David Charles Daniel

Michael T DeKeuster

James A Dykens

Robert Terkeltaub

Hironori Yamashita

Christopher J Hockett

William Paul Findlay

Sophie Dutheil

Thomas G Seador

John Evanyo

Robert Michael Romano

Daniel Isaac Armstrong

Daniel Edgar Nelson

Gonul Velecelebi

Masahiro Takasuga

Allan K Uldan

Anna-Maria Frost-Jensen, Legal Representative

Andrew E Granston, Jr

Michael T Dekeuster

Shelby I Sullivan

The disclosure provides methods the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis, and for protecting or reinforcing the blood-brain barrier, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT.

Methods

The invention relates to pharmaceutical compositions comprising the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine Dreceptor signaling, sodium channel activity, and/or norepinephrine transporter activity.

Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders

The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, including methods of treatment and pharmaceutical compositions for use therein.

Methods of treating inflammatory disease

In variants, the method for automatic debris detection includes: determining a region image; optionally determining a parcel representation for the region image; generating a debris representation using the region image; generating a debris score based on the debris representation; and optionally monitoring the debris score over time.

Method and system for automated debris detection

This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HTreceptor, serotonin transporter (SERT) and/or pathways involving dopamine D/Dreceptor signaling systems, and/or the treatment of residual symptoms.

Organic compounds

The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Transmucosal methods for treating psychiatric and neurological conditions

The invention relates to pharmaceutical compositions comprising compounds of Formula Q: wherein W is —N(CH)—, and Y is —C(O)—, in free base or pharmaceutically acceptable salt form, and methods of use in the treatment of diseases involving 5-HTreceptor, serotonin transporter (SERT) pathway and/or the dopamine Dreceptor pathway, and methods of treating conditions of the central nervous system therewith.

Pharmaceutical compositions comprising 4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one for treating central nervous system disorders

A quick-release latch may include a male component and a female component. The male component may include an insertable male portion comprising a top wall, a bottom wall, and one or more sidewalls. The male component may also include a first strap attachment portion defining a first plurality of strap openings each having a laterally extending strap slot and a mouth positioned off-center of and providing exterior access to the respective strap slot. The female component may include a female receptacle portion comprising a top wall, a bottom wall, and one or more sidewalls collectively forming a receptacle configured to receive and releasably lock to the insertable male portion of the male component. The top wall of the female receptacle may include a cantilever wall partially surrounded by one or more slots. The cantilever wall may extend proximate a same plane as the top wall.

Quick-release latches

The invention relates to pharmaceutical compositions comprising compounds of Formula Q: wherein W is —N(CH)—, and Y is —CH(OH)—, in free base or pharmaceutically acceptable salt form, and methods of use in the treatment of diseases involving 5-HTreceptor, serotonin transporter (SERT) pathway and/or the dopamine Dreceptor pathway, and methods of treating conditions of the central nervous system therewith.

Pharmaceutical compositions comprising 4-((6bR, 10aS)-3-methyl-2,3,6b,9,10, 10a-hexahydro-1H,7H-pyrido[3',4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-ol for treating central nervous system disorders

An interchangeable module configured to be used in an integrated perforating gun and setting tool system, the interchangeable module having a body having a chamber, a first electrical connection located at a first end of the chamber, and a second electrical connection located at a second end of the chamber. The first end is opposite to the second end. An addressable switch located inside the chamber, the addressable switch has a digital address. A connection unit located inside the chamber and configured to electrically connect the addressable switch to an initiating device. The interchangeable module is configured to be used (1) between a first gun cluster and a second gun cluster and (2) between a distal gun cluster and a setting tool, and the first and second electrical connections are electrically connected to the addressable switch.

Integrated perforating gun and setting tool system and method

The invention relates to a particular substituted heterocycle fused gamma-carboline, in free, or pharmaceutically acceptable salt, and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HTreceptor, the serotonin transporter (SERT), and/or pathways involving the dopamine Dand Dreceptor signaling system.

Organic compound

The invention relates to a particular enantiomer of a substituted heterocycle fused gamma-carboline, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HTreceptor, and pathways involving the dopamine Dand Dreceptor signaling system.

The disclosure provides methods, treatments and materials for treating diseases or disorders associated with the dopamine D1 receptor intracellular pathway. In particular, the present disclosure provides for methods of treating such diseases and disorders in combination with a dopamine replacement therapy.

Uses

The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HTreceptor, the serotonin transporter (SERT), pathways involving the dopamine Dand Dreceptor signaling system, and/or the μ-opioid receptor.

Pharmaceutical compositions comprising heterocycle fused gamma carboline prodrugs

The disclosure provides new transdermal pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Compositions and methods

Growing community of inventors

San Diego, CA, United States of America

Robert E Davis